We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. An independent data monitoring committee has ruled that ...
-- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year -- “We are pleased that after reviewing the Cohort 1 data from our ELEVATE-44-201 study, the ...
ChemoCentryx, the $3.7 billion biotech bought by Amgen in 2022, allegedly ignored repeated warnings from a data monitoring committee and withheld or manipulated trial results on the firm’s ...
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel ...
NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...
SYDNEY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the XanaMIA pivotal Alzheimer’s disease (AD) trial’s independent Data Monitoring Committee (DMC) has ...
After a data monitoring committee found that one of Relmada Therapeutics' late-stage trials in major depressive disorder (MDD) would likely miss its main goal, the biotech has scrapped two phase 3 ...
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today ...
Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to progress Phase 1 to the next dose level ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results